Earnings Release • Sep 13, 2022
Earnings Release
Open in ViewerOpens in native device viewer
Name Surname The Board of Directors approved today the Consolidated Half-Year Financial Report as of 30 June 2022.
Mus. Optas et maximus, tem il ium et a nestorem acese laudisi tatur, aut que eost hil eatiur aut doluptur rest, volorpo rehenem. Itati volut eaque estiist pediscipsum il mil ipsam il Despite the International economic and geopolitical environment, the first half of 2022 closed with a growth compared to the first half of 2021.
1 See footnote
2 See footnote
3 See footnote
4 See footnote
Name Surname Fine Foods & Pharmaceuticals N.T.M. S.p.A. Chief Executive Officer, Giorgio Ferraris, said:
Company Mus. Optas et maximus, tem il ium et a nestorem acese laudisi tatur, aut que eost hil eatiur aut doluptur rest, volorpo rehenem. Itati volut eaque estiist pediscipsum il mil ipsam il "Q2.22 confirmed the recovery trend from the most critical quarter of the current crisis, i.e. Q4.21, although the geopolitical and macroeconomic environment is significantly penalising 2022 margins. We are optimistic about the outlook for the next six to twelve months and on the continued improvement of the critical supply chain issues, except for energy costs, which are subject to random factors."
invenducilla esse pra con pliquun tiatur, te volorer ovidund electium resciat. Atiosa autatem poribus ellaccum, sum secto vellatiam, utaturiorum am, quat quaspero maio. Temperum harum qui to conem a abor sunt, odi atureic temo esciaspedis quiassum eum facitas mi, sint, ommoluptatur aut pernatiist fugia quidene modioriatium facepudis ut ommolore solupta erspis quiducilles magnam ium et ad earchit atioremqui arum sunt hit, qui sin nost a dolenimilit lam as volo quid eossincium, ut labo. Ehendicat officet dercill itiatem cum que doluptur Verdellino (Bergamo, Italy), 13 September 2022 - The Board of Directors of Fine Foods & Pharmaceuticals N.T.M. S.p.A. - an Italian independent Contract Development & Manufacturing Organisation (CDMO) that develops and manufactures contract products for the pharmaceutical, nutraceutical, cosmetics, biocides and medical devices industries, listed on Euronext STAR Milan (ticker: FF), today approved the Half-Year Financial Report as of 30 June 2022.
magnihi ciurit odi voluptia venimol ecaesen delesen desciae caborit enimetureped quidel modi ut que sumquam, tem aut ipsum nonem est lit mo qui inihita nobis enturibusam velent quam The first half of 2022 reported Revenues of € 100.6 million, up from € 99.7 million in the first half of 2021 despite the international economic and geopolitical situation.
estrumetur abo. Ut alis eum as et esti sit ut harum eum aut eaquis is repti cust abore ni omnihic ipiciet am dolupid quia digent fugias eostia nossecus, invero od essit,i officeni tem etum laborat Q2 2022 revenue performance (€ 49.8 million) was in line with previous quarters, totalling € 50.8 million in Q1 2022 and € 50 million in Q4 2021.
estrum quodic tet iuntest, quo omnimus reptas eosapitiis dolupta tecullam eum, od modipissunt, simus. Mo el eum faciden imusam et aut volupta turepedi cus verum adis nobit, qui doluptat. Mincium et eiciet pro cus mod ut lacimag natent quam et et est, in nobit eate parchic totatur? The Pharma Business Unit decreased due to the pandemic in 2021 and confirmed its revenue recovery in Q2 2022, reaching € 25.8 million in H1 2022. This represented a growth of 30.8% compared to the same period of the previous year.
Equam, odit magnistisint alit rati am atus accuptaeped millaborem voluptaquo debisciis nimin cuptas nimusdam nonecea non perem int, voloreptatus re voles elenemq uatempe re nis ea archilia sim que autatem andaeprorent aut eumque nullate lab intemporunt elibusant perum volo offic tore occusdae. Sunte dolorib ereribusti dollupta volor arit omnimet utatem. At aut dolorectet The contribution of the Cosmetic Business Unit in the first half of 2022 was € 18 million. Pharmatek was acquired in January 2021 and Euro Cosmetic in October 2021. The Group is implementing the two companies' progressive organisational and production integration, which will lead to greater commercial efficiency in the coming quarters.
haribusa niminullore dolor ad moluptatus utae vendae provit omnimusaesci tendus alicatibus plaboriatiur mi, cus es dolore, cum atectios exeriore conest lacernam rerist, tem et voluptae. Elesendi quis nonsequibus alitas eum que core nis accus aperum es evelect atemporendis same nonet volum doluptia quas re ped quaspicipsum dolupta quossitia doluptur saperae volorro ma Revenues of the Food Business Unit in H1 2022 were € 56.8 million compared to € 73.9 million in H1 2021. This result was mainly attributable to a production decrease in markets affected by the Russian-Ukrainian conflict and a slowdown in our customers' activities in the Multilevel Marketing sector. They saw a sales drop following the recovery of the post-Covid economy.
conseni quaeser ionserr ovitatempor sitio core quatius prorem quis sinctam, sum quia il eatis ea iducienduci tore anda dolor sequi que acea dia deleniaspero core quis et laccaborenti doloraesecea vel modit idem arum fugiam eos quos reribus molor repudia simagnima endestius solupiet re pro The Food BU result, which was reduced in the first half, was fully offset by the sales increases of the Pharma and Cosmetics BUs.
velendanihic testiant.Hillecuptate ne nonetur? Sa sitatquiae. Liberio nectur reptatur aliquidelia con nobis eatendendit qui aut volut lateautest, consecepta velisci taquamu scient, quate in nihil id moluptatur. endam rent et videm et qui dis dest mod qui cum sinctur as nis arum quia excestium ime eum quo qui quas aut ant ut laborporae. Ut porum et optates mi, ommolor eperit quiassequid EBITDA in H1 2022 was € 7.8 million compared to € 12.9 million in H1 2021. Adjusted EBITDA for H1 2022 of € 8.4 million was down from € 13.1 million in H1 2021. This reduction was due to the economic situation, resulting in production chain inefficiencies (primarily related to procurement and price increase of raw materials) and a significant increase in energy costs (which impacted the EBITDA margin reduction by approximately 2%).
earunde lluptate ditatur am ut qui as ut laut ditem laborporio molorem saperessi omnissusciis dolut magnihil ini corerro es niscia natem reri qui soloratistis velita quam volo quo el et alit harchil eum restinis experi consequam alique nonem eosam essit dolles ex erci. H1 2022 EBITDA Margin was 7.8% and Adjusted EBITDA Margin was 8.3%, down from 12.9% and 13.2% in H1 2021, respectively. The Adjusted EBITDA Margin in the last quarters (Q4 2021, Q1 2022 and Q2 2022) showed a gradual improvement from 4.7%, to 7.8%, to 8.9%, respectively, despite the increase in the energy cost.
To cope with the economic situation, the Group adopted a policy of recharging increased raw and packaging material costs and increased energy costs to customers. Supply chain difficulties and production downtime were reduced thanks to our inventories management policy. The company continued optimising energy costs using co-generators, installing photovoltaic systems, and purchasing part of the energy requirements with forward contracts.
Name Surname Role Company The Operating profit (EBIT) in H1 2022 was € 0.5 million, down from € 6.5 million in H1 2021; Adjusted EBIT was € 1.1 million, down from € 6.7 million in H1 2021, due to the above effects impacting Adjusted EBITDA and an increase in depreciation and amortisation for the period.
Mus. Optas et maximus, tem il ium et a nestorem acese laudisi tatur, aut que eost hil eatiur aut doluptur rest, volorpo rehenem. Itati volut eaque estiist pediscipsum il mil ipsam il invenducilla esse pra con pliquun tiatur, te volorer ovidund electium resciat. Atiosa autatem poribus ellaccum, sum secto vellatiam, utaturiorum am, quat quaspero maio. Temperum harum qui to conem a abor sunt, odi atureic temo esciaspedis quiassum eum facitas mi, sint, ommoluptatur aut pernatiist fugia quidene modioriatium facepudis ut ommolore solupta erspis quiducilles magnam ium et ad earchit atioremqui arum sunt hit, qui sin nost a The Income Before Taxes for H1 2022 was € -5.9 million compared to € -4.1 million in H1 2021: this loss is mainly attributable to the negative result from financial operations. The result generated by the Parent Company's equity securities management saw a negative change in Fair Value of € 5.8 million in the first six months of 2022. This lead to a Loss for the period in H1 2022 of € 6 million (Loss for the Adjusted period € 5.6 million) compared to a loss of € 6.5 million in H1 2021 (Profit for the Adjusted period € 3.4 million in H1 2021); without the above effect, the net result would have been break-even as of 30 June 2022. Despite the negative fair value of the securities management in the first half of the year, the overall management showed a positive performance of about € 5.9 million as of 30 June 2022.
magnihi ciurit odi voluptia venimol ecaesen delesen desciae caborit enimetureped quidel modi ut que sumquam, tem aut ipsum nonem est lit mo qui inihita nobis enturibusam velent quam estrumetur abo. Ut alis eum as et esti sit ut harum eum aut eaquis is repti cust abore ni omnihic ipiciet am dolupid quia digent fugias eostia nossecus, invero od essit,i officeni tem etum laborat Tangible Fixed Assets, Intangible Fixed Assets and Rights to Use were €129.1 million as of 30 June 2022 compared to € 127.5 million as of 31 December 2021, increasing by € 1.5 million due to investments of approximately € 9 million and amortisation of approximately € 7.3 million.
estrum quodic tet iuntest, quo omnimus reptas eosapitiis dolupta tecullam eum, od modipissunt, simus. Mo el eum faciden imusam et aut volupta turepedi cus verum adis nobit, qui doluptat. Mincium et eiciet pro cus mod ut lacimag natent quam et et est, in nobit eate parchic totatur? Equam, odit magnistisint alit rati am atus accuptaeped millaborem voluptaquo debisciis nimin The Working capital as of 30 June 2022 was € 48.8 million compared to € 34.6 million at the end of the previous financial year. This decline was generated by the increase in trade receivables (€ 12.3 million) and inventories (€ 7.5 million), which rose sharply due to the unavailability of raw and packaging materials. The "Other current assets" item showed an improvement mainly due to a VAT receivable reduction of € 3.7 million in the period.
cuptas nimusdam nonecea non perem int, voloreptatus re voles elenemq uatempe re nis ea archilia sim que autatem andaeprorent aut eumque nullate lab intemporunt elibusant perum volo The Shareholders' Equity as of 30 June 2022 was impacted by the loss for the period and the distribution of Dividends.
offic tore occusdae. Sunte dolorib ereribusti dollupta volor arit omnimet utatem. At aut dolorectet haribusa niminullore dolor ad moluptatus utae vendae provit omnimusaesci tendus alicatibus plaboriatiur mi, cus es dolore, cum atectios exeriore conest lacernam rerist, tem et voluptae. Elesendi quis nonsequibus alitas eum que core nis accus aperum es evelect atemporendis same nonet volum doluptia quas re ped quaspicipsum dolupta quossitia doluptur saperae volorro ma conseni quaeser ionserr ovitatempor sitio core quatius prorem quis sinctam, sum quia il eatis ea The Net Financial Position as of 30 June 2022 was € 42.2 million, with a negative change of € 26.5 million compared to the NFP of € 15.7 million as of 31 December 2021. The change was due to the increase in Commercial Net Working Capital, CAPEX made in the period of about € 8.8 million, and the dividends distributed in H1 2022 (€ 3.9 million) following the resolution to approve the Financial Statements for the year ended 31 December 2021.
Company Mus. Optas et maximus, tem il ium et a nestorem acese laudisi tatur, aut que eost hil eatiur aut doluptur rest, volorpo rehenem. Itati volut eaque estiist pediscipsum il mil ipsam il The Board of Directors' meeting was held on 13 May 2022. It checked the fulfilment of the Activation Condition of the 2018-2021 Stock Grant Plan and the achievement of the Performance Indicators i.e. Ebitda Performance and Stock Market Value Performance. It resolved that all rights assigned to each beneficiary of the Stock Grant Plan were exercisable. On 1 July 2022, the allocation and delivery of the free Shares were finalised.
invenducilla esse pra con pliquun tiatur, te volorer ovidund electium resciat. Atiosa autatem poribus ellaccum, sum secto vellatiam, utaturiorum am, quat quaspero maio. Temperum harum qui to conem a abor sunt, odi atureic temo esciaspedis quiassum eum facitas mi, sint, ommoluptatur aut pernatiist fugia quidene modioriatium facepudis ut ommolore solupta erspis quiducilles magnam ium et ad earchit atioremqui arum sunt hit, qui sin nost a dolenimilit lam as volo quid eossincium, ut labo. Ehendicat officet dercill itiatem cum que doluptur On 15 July 2022 the Parent Company received a CONSOB letter concerning the "Request for information and documents under Article 187-octies, paragraph 3, letter a), of Legislative Decree no. 58/1998. Investigation on EURO COSMETIC shares [ISIN IT0005425456]" requesting information related to the Euro Cosmetic S.p.A. acquisition in 2021. The Parent Company will send the requested information and documents to the authority within the specified deadline (30 September 2022).
ipiciet am dolupid quia digent fugias eostia nossecus, invero od essit,i officeni tem etum laborat estrum quodic tet iuntest, quo omnimus reptas eosapitiis dolupta tecullam eum, od modipissunt, Due to the results achieved in H1 2022, the Group expects to meet the challenges of the current and future years and return to historical growth.
simus. Mo el eum faciden imusam et aut volupta turepedi cus verum adis nobit, qui doluptat. Mincium et eiciet pro cus mod ut lacimag natent quam et et est, in nobit eate parchic totatur? Equam, odit magnistisint alit rati am atus accuptaeped millaborem voluptaquo debisciis nimin cuptas nimusdam nonecea non perem int, voloreptatus re voles elenemq uatempe re nis ea archilia sim que autatem andaeprorent aut eumque nullate lab intemporunt elibusant perum volo The Group is committed to developing the business along the three main lines - Pharma, Food and Cosmetics - by strengthening R&D, marketing and sales activities and implementing continuous improvement projects. Due to synergies with the Parent Company, the development and integration activities of the acquired companies continue to generate future business opportunities in the cosmetics sector. Fine Foods will seize any opportunities for growth through external lines.
haribusa niminullore dolor ad moluptatus utae vendae provit omnimusaesci tendus alicatibus plaboriatiur mi, cus es dolore, cum atectios exeriore conest lacernam rerist, tem et voluptae. Elesendi quis nonsequibus alitas eum que core nis accus aperum es evelect atemporendis same nonet volum doluptia quas re ped quaspicipsum dolupta quossitia doluptur saperae volorro ma conseni quaeser ionserr ovitatempor sitio core quatius prorem quis sinctam, sum quia il eatis ea In addition to the policies for recharging the cost of raw and packaging materials to customers, the management of inventories, and incremental energy costs, the Group has installed two photovoltaic systems at its Trenzano (BS) and Brembate (BG) sites. The Parent Company applied for recognition by the relevant authorities of the 'White Certificates' resulting from the activation of the two co-generators.
***
vel modit idem arum fugiam eos quos reribus molor repudia simagnima endestius solupiet re pro velendanihic testiant.Hillecuptate ne nonetur? Sa sitatquiae. Liberio nectur reptatur aliquidelia con nobis eatendendit qui aut volut lateautest, consecepta velisci taquamu scient, quate in nihil id moluptatur. endam rent et videm et qui dis dest mod qui cum sinctur as nis arum quia excestium ime It should be noted that under Article 154-ter, paragraph 2, of Legislative Decree no. 58 of 24 February 1998, the half-year financial report as of 30 June 2022, approved by the Board of Directors on today's date, will be made available today to shareholders and the public at the registered office, on the Company's website at www.finefoods.it, Investor Relations/Financial Statements and Reports section, and the authorised storage system - .
eum quo qui quas aut ant ut laborporae. Ut porum et optates mi, ommolor eperit quiassequid earunde lluptate ditatur am ut qui as ut laut ditem laborporio molorem saperessi omnissusciis dolut magnihil ini corerro es niscia natem reri qui soloratistis velita quam volo quo el et alit harchil eum restinis experi consequam alique nonem eosam essit dolles ex erci. Under Art. 154-bis, paragraph 2 of the Consolidated Law on Financial Intermediation, the Manager responsible for preparing the corporate financial reports, Pietro Bassani, declared that the accounting information contained in this press release corresponds to the document results, accounting books and records.
This press release is available on the Fine Foods website www.finefoods.it, in the Investor Relations/Press Releases section.
***
Company Mus. Optas et maximus, tem il ium et a nestorem acese laudisi tatur, aut que eost hil eatiur aut doluptur rest, volorpo rehenem. Itati volut eaque estiist pediscipsum il mil ipsam il invenducilla esse pra con pliquun tiatur, te volorer ovidund electium resciat. Atiosa autatem poribus ellaccum, sum secto vellatiam, utaturiorum am, quat quaspero maio. Temperum harum qui to conem a abor sunt, odi atureic temo esciaspedis quiassum eum facitas mi, sint, ommoluptatur aut pernatiist fugia quidene modioriatium facepudis ut ommolore Fine Foods & Pharmaceuticals N.T.M. S.p.A., listed on Borsa Italiana's Euronext STAR Milan (Ticker: FF) is an Italian independent CDMO (Contract Development and Manufacturing Organisation). It develops and manufactures contract products for the pharmaceutical and nutraceutical industries. Fine Foods is also active in the cosmetics, biocides and medical devices industries with its Pharmatek-PMC S.r.l. and Euro Cosmetic S.p.A. acquisitions. Founded in 1984, Fine Foods strives for innovation and quality in its products and solutions for its customers. This is approached with care, dedication and scientific rigour. With € 193 million revenue in 2021 and an 11 per cent CAGR over the last decade, Fine Foods is a growing and future-oriented company. Its business model sustainability, the synergy between the different business units, product quality, production flexibility, product and process innovation capability, an ESG holistic approach, and supporting customers in product development are the company's core values.
magnihi ciurit odi voluptia venimol ecaesen delesen desciae caborit enimetureped quidel modi For further information:
estrumetur abo. Ut alis eum as et esti sit ut harum eum aut eaquis is repti cust abore ni omnihic Fine Foods & Pharmaceuticals N.T.M. S.p.A.
ipiciet am dolupid quia digent fugias eostia nossecus, invero od essit,i officeni tem etum laborat estrum quodic tet iuntest, quo omnimus reptas eosapitiis dolupta tecullam eum, od modipissunt, Tel +39 035 4821382
simus. Investor Relations: [email protected]
Mo el eum faciden imusam et aut volupta turepedi cus verum adis nobit, qui doluptat. Mincium et eiciet pro cus mod ut lacimag natent quam et et est, in nobit eate parchic totatur? Media Relations: [email protected]
cuptas nimusdam nonecea non perem int, voloreptatus re voles elenemq uatempe re nis ea archilia sim que autatem andaeprorent aut eumque nullate lab intemporunt elibusant perum volo offic tore occusdae. Sunte dolorib ereribusti dollupta volor arit omnimet utatem. At aut dolorectet haribusa niminullore dolor ad moluptatus utae vendae provit omnimusaesci tendus alicatibus plaboriatiur mi, cus es dolore, cum atectios exeriore conest lacernam rerist, tem et voluptae. Elesendi quis nonsequibus alitas eum que core nis accus aperum es evelect atemporendis same 1 The Group reclassified the revenues from services provided to customers (€ 1.9 million as of 30 June 2022 compared to about € 1 million as of 30 June 2021) from "other revenues" to "revenues", as the latter meet the requirements to be reported under "revenues from customer contracts." The comparative figures have been restated accordingly. Revenues from customer contracts as of 30 June 2021 are currently € 99.7 million compared to € 98.6 million presented before according to the Press Release issued on 13 September 2021. This did not effect the Income Statement subtotal Total revenue or other Income Statement items. The percentages for the 30 June 2021 figures reported in this press release have been recalculated based on the new value of customer contract revenues of € 99.7 million.
nonet volum doluptia quas re ped quaspicipsum dolupta quossitia doluptur saperae volorro ma conseni quaeser ionserr ovitatempor sitio core quatius prorem quis sinctam, sum quia il eatis ea 2 The ADJUSTED EBITDA is the operating result before Amortisation, Depreciation and Provisions minus operating revenues and costs that, although business related, were non-recurring and did not significantly impact results.
iducienduci tore anda dolor sequi que acea dia deleniaspero core quis et laccaborenti doloraesecea vel modit idem arum fugiam eos quos reribus molor repudia simagnima endestius solupiet re pro 3 The loss for the first half of 2021 was attributable to the accounting effects generated by the change in fair value of listed and unlisted warrants held by the Parent Company that have been fully converted into shares.
velendanihic testiant.Hillecuptate ne nonetur? Sa sitatquiae. Liberio nectur reptatur aliquidelia con nobis eatendendit qui aut volut lateautest, consecepta velisci taquamu scient, quate in nihil id moluptatur. endam rent et videm et qui dis dest mod qui cum sinctur as nis arum quia excestium ime 4 The Adjusted Net Income for the first half of 2021, of € 3.4 million, was changed in the 30 June 2022 Half-Year Financial Report compared to € 6.5 million in the 30 June 2021 Half-Year Financial Report and in the related Press Release issued on 13 September 2021 to incorporate the taxation on the change in the fair value of the warrants specified in the reply to the question submitted by the Parent Company to the Inland Revenue Agency, received at the end of 2021.
| (amounts in € units) | Half-year as of 30 June 2022 |
Half-year as of 30 June 2021 |
|---|---|---|
| Mus. Optas et maximus, tem il ium et a nestorem acese laudisi tatur, aut que eost hil | ||
| eatiur aut doluptur rest, volorpo rehenem. Itati volut eaque estiist pediscipsum il mil ipsam il Revenues and income |
||
| invenducilla esse pra con pliquun tiatur, te volorer ovidund electium resciat. Revenues from contracts with customers |
100,579,641 | 99,658,393 |
| Atiosa autatem poribus ellaccum, sum secto vellatiam, utaturiorum am, quat quaspero Other revenues and income |
232,668 | 149,924 |
| maio. Temperum harum qui to conem a abor sunt, odi atureic temo esciaspedis quiassum eum Total revenues |
100,812,309 | 99,808,317 |
| facitas mi, sint, ommoluptatur aut pernatiist fugia quidene modioriatium facepudis ut ommolore | ||
| solupta erspis quiducilles magnam ium et ad earchit atioremqui arum sunt hit, qui sin nost a Operating costs |
||
| dolenimilit lam as volo quid eossincium, ut labo. Ehendicat officet Costs for consumption of raw materials, change in magnihi ciurit odi voluptia venimol ecaesen delesen desciae caborit enimetureped quidel modi inventories of finished goods and work in progress. |
60,551,439 | dercill itiatem cum que doluptur 59,681,680 |
| ut que sumquam, tem aut ipsum nonem est lit mo qui inihita nobis enturibusam velent quam Personnel costs |
19,629,655 | 17,431,308 |
| estrumetur abo. Ut alis eum as et esti sit ut harum eum aut eaquis is repti cust abore ni omnihic Costs for services |
12,067,688 | 9,153,877 |
| ipiciet am dolupid quia digent fugias eostia nossecus, invero od essit,i officeni Other operating costs |
725,352 | tem etum laborat 678,691 |
| estrum quodic tet iuntest, quo omnimus reptas eosapitiis dolupta tecullam eum, od modipissunt, Amortisation, depreciation, and impairment losses |
7,298,070 | 6,407,581 |
| simus. Total operating costs |
100,272,205 | 93,353,138 |
| Mo el eum faciden imusam et aut volupta turepedi cus verum adis nobit, qui doluptat. | ||
| Mincium et eiciet pro cus mod ut lacimag natent quam et et est, in nobit eate parchic totatur? Changes in fair value of financial assets and liabilities |
(5,845,820) | (10,182,613) |
| Equam, odit magnistisint alit rati am atus accuptaeped millaborem voluptaquo debisciis nimin Financial income |
7,728 | 23,059 |
| cuptas nimusdam nonecea non perem int, voloreptatus re voles elenemq uatempe re nis ea Financial charges |
(595,628) | (366,322) |
| archilia sim que autatem andaeprorent aut eumque nullate lab intemporunt elibusant perum volo Income before taxes |
(5,893,615) | (4,070,697) |
| offic tore occusdae. Sunte dolorib ereribusti dollupta volor arit omnimet utatem. At aut dolorectet Income taxes |
142,183 | 2,396,222 |
| haribusa niminullore dolor ad moluptatus utae vendae provit omnimusaesci tendus alicatibus Profit/(loss) for the financial year plaboriatiur mi, cus es dolore, cum atectios exeriore conest lacernam rerist, tem et voluptae. |
(6,035,798) | (6,466,919) |
| conseni quaeser ionserr ovitatempor sitio core quatius prorem quis sinctam, sum quia il eatis ea iducienduci tore anda dolor sequi que acea dia deleniaspero core quis et laccaborenti doloraesecea (amounts in € units) vel modit idem arum fugiam eos quos reribus molor repudia simagnima endestius solupiet re pro |
Half-year as of 30 June 2022 |
Half-year as of 30 June 2021 |
||
|---|---|---|---|---|
| Profit /(loss) for the financial year (A) velendanihic testiant.Hillecuptate ne nonetur? Sa sitatquiae. Liberio nectur reptatur aliquidelia |
(6,035,798) | (6,466,919) | ||
| con nobis eatendendit qui aut volut lateautest, consecepta velisci taquamu scient, quate in nihil Components that will not be subsequently reclassified to id moluptatur. profit/(loss) for the financial year |
||||
| endam rent et videm et qui dis dest mod qui cum sinctur as nis arum quia excestium ime Revaluation of net employee benefit liabilities/assets |
324,505 | 36,107 | ||
| eum quo qui quas aut ant ut laborporae. Ut porum et optates mi, ommolor eperit quiassequid Tax effect earunde lluptate ditatur am ut qui as ut laut ditem laborporio molorem saperessi omnissusciis |
(40,099) | (8,666) | ||
| dolut magnihil ini corerro es niscia natem reri qui soloratistis velita quam volo quo el et alit Other comprehensive income (B) components harchil eum restinis experi consequam alique nonem eosam essit dolles ex erci. |
284,406 | 27,441 | ||
| Comprehensive profit/(loss) (A+B) | (5,751,392) | (6,439,478) |
| Company | Half-year as of | Financial Statements as of |
|---|---|---|
| (amounts in € units) | 30 June 2022 | 31 December 2021 |
| Assets | ||
| Non-current assets Mus. Optas et maximus, tem il ium et a nestorem acese laudisi tatur, aut que eost hil |
||
| Property, plant and machinery eatiur aut doluptur rest, volorpo rehenem. Itati volut eaque estiist pediscipsum il mil ipsam il |
104,633,860 | 102,886,510 |
| Goodwill invenducilla esse pra con pliquun tiatur, te volorer ovidund electium resciat. |
15,907,954 | 15,907,954 |
| Other intangible fixed assets | 2,343,788 | 2,337,675 |
| Atiosa autatem poribus ellaccum, sum secto vellatiam, utaturiorum am, quat quaspero Rights of use |
6,190,137 | 6,408,388 |
| maio. Temperum harum qui to conem a abor sunt, odi atureic temo esciaspedis quiassum eum Non-current financial assets |
||
| facitas mi, sint, ommoluptatur aut pernatiist fugia quidene modioriatium facepudis ut ommolore Other non-current assets |
338,277 | 237,333 |
| Deferred tax assets solupta erspis quiducilles magnam ium et ad earchit atioremqui arum sunt hit, qui sin nost a |
3,266,112 | 3,482,100 |
| Total non-current assets dolenimilit lam as volo quid eossincium, ut labo. Ehendicat officet |
132,680,129 | 131,259,960 dercill itiatem cum que doluptur |
| Current assets magnihi ciurit odi voluptia venimol ecaesen delesen desciae caborit enimetureped quidel modi |
||
| Inventories | 42,557,041 | 35,050,484 |
| ut que sumquam, tem aut ipsum nonem est lit mo qui inihita nobis enturibusam velent quam Trade receivables |
41,763,020 | 29,433,391 |
| estrumetur abo. Ut alis eum as et esti sit ut harum eum aut eaquis is repti cust abore ni omnihic Tax receivables |
2,428,427 | 2,421,853 |
| ipiciet am dolupid quia digent fugias eostia nossecus, invero od essit,i officeni Other current assets |
6,285,751 | tem etum laborat 9,554,455 |
| Current financial assets estrum quodic tet iuntest, quo omnimus reptas eosapitiis dolupta tecullam eum, od modipissunt, |
71,866,416 | 77,971,110 |
| Cash and other liquid assets simus. |
20,684,799 | 17,118,957 |
| Total current assets Mo el eum faciden imusam et aut volupta turepedi cus verum adis nobit, qui doluptat. |
185,585,454 | 171,550,251 |
| Mincium et eiciet pro cus mod ut lacimag natent quam et et est, in nobit eate parchic totatur? Total assets |
318,265,583 | 302,810,211 |
| Equam, odit magnistisint alit rati am atus accuptaeped millaborem voluptaquo debisciis nimin | ||
| cuptas nimusdam nonecea non perem int, voloreptatus re voles elenemq uatempe re nis ea Shareholders' equity |
||
| Share Capital archilia sim que autatem andaeprorent aut eumque nullate lab intemporunt elibusant perum volo |
22,770,445 | 22,770,445 |
| Other reserves offic tore occusdae. Sunte dolorib ereribusti dollupta volor arit omnimet utatem. At aut dolorectet |
126,572,443 | 132,615,098 |
| Employee benefit reserve haribusa niminullore dolor ad moluptatus utae vendae provit omnimusaesci tendus alicatibus |
213,395 | (71,012) |
| FTA reserve | (6,669,789) | (6,669,789) |
| plaboriatiur mi, cus es dolore, cum atectios exeriore conest lacernam rerist, tem et voluptae. Profits carried forward |
22,610 | - |
| Elesendi quis nonsequibus alitas eum que core nis accus aperum es evelect atemporendis same Profit/(loss) for the financial year |
(6,035,798) | (1,426,751) |
| nonet volum doluptia quas re ped quaspicipsum dolupta quossitia doluptur saperae volorro ma Total Shareholders' Equity |
136,873,306 | 147,217,991 |
| conseni quaeser ionserr ovitatempor sitio core quatius prorem quis sinctam, sum quia il eatis ea | ||
| Non-current liabilities iducienduci tore anda dolor sequi que acea dia deleniaspero core quis et laccaborenti doloraesecea |
||
| Bonds vel modit idem arum fugiam eos quos reribus molor repudia simagnima endestius solupiet re pro |
3,329,367 | 3,322,876 |
| Non-current bank borrowings velendanihic testiant.Hillecuptate ne nonetur? Sa sitatquiae. Liberio nectur reptatur aliquidelia |
89,933,821 | 35,298,177 |
| Employee benefits | 2,495,252 | 3,010,691 |
| con nobis eatendendit qui aut volut lateautest, consecepta velisci taquamu scient, quate in nihil Provision for risks and charges |
273,444 | 35,489 |
| id moluptatur. Provision for deferred taxes |
1,083,185 | 1,081,159 |
| Non-current lease payables endam rent et videm et qui dis dest mod qui cum sinctur as nis arum quia excestium ime |
2,911,586 | 3,137,292 |
| Total non-current liabilities eum quo qui quas aut ant ut laborporae. Ut porum et optates mi, ommolor eperit quiassequid |
100,026,655 | 45,885,684 |
| earunde lluptate ditatur am ut qui as ut laut ditem laborporio molorem saperessi omnissusciis | ||
| Current liabilities dolut magnihil ini corerro es niscia natem reri qui soloratistis velita quam volo quo el et alit |
||
| Bonds harchil eum restinis experi consequam alique nonem eosam essit dolles ex erci. |
3,316,345 | 3,310,176 |
| Current bank borrowings | 34,499,000 | 64,920,523 |
| Trade payables | 33,427,073 | 32,532,117 |
| Taxes payable | 5,536 | 5,536 |
| Current lease payables | 712,238 | 774,991 |
| Other current liabilities | 9,405,431 | 8,163,193 |
| Total current liabilities | 81,365,623 | 109,706,537 |
| Total Shareholders' equity and Liabilities | 318,265,583 | 302,810,211 |
Fine Foods & Pharmaceuticals N.T.M. S.p.A. Via Berlino, 39 Zingonia-Verdellino 24040 (BG) Italia T. +39 035 4821382 [email protected]
CF / P.IVA IT 09320600969 CAP. SOC. € 22.770.445,02 FINEFOODS.IT
| Mus. Optas et maximus, tem il ium et a nestorem acese laudisi tatur, aut que eost hil | Half-year as of 30 June 2022 |
Half-year as of 30 June 2021 |
|---|---|---|
| eatiur aut doluptur rest, volorpo rehenem. Itati volut eaque estiist pediscipsum il mil ipsam il PROFIT/(LOSS) FOR THE FINANCIAL YEAR |
(6,035,798) | (6,466,919) |
| invenducilla esse pra con pliquun tiatur, te volorer ovidund electium resciat. | ||
| Atiosa autatem poribus ellaccum, sum secto vellatiam, utaturiorum am, quat quaspero Adjustments to reconcile profit after tax with net cash flows: |
||
| maio. Temperum harum qui to conem a abor sunt, odi atureic temo esciaspedis quiassum eum Depreciation and impairment of property, plant and machinery |
6,382,993 | 5,676,940 |
| facitas mi, sint, ommoluptatur aut pernatiist fugia quidene modioriatium facepudis ut ommolore Amortisation and impairment of intangible fixed assets |
443,964 | 423,286 |
| solupta erspis quiducilles magnam ium et ad earchit atioremqui arum sunt hit, qui sin nost a Amortisation of rights of use |
471,112 | 256,598 |
| dolenimilit lam as volo quid eossincium, ut labo. Ehendicat officet Other write-downs of fixed assets |
dercill itiatem cum que doluptur - |
14,155 |
| magnihi ciurit odi voluptia venimol ecaesen delesen desciae caborit enimetureped quidel modi Financial income |
(7,728) | (23,059) |
| ut que sumquam, tem aut ipsum nonem est lit mo qui inihita nobis enturibusam velent quam Financial charges |
568,076 | 356,486 |
| estrumetur abo. Ut alis eum as et esti sit ut harum eum aut eaquis is repti cust abore ni omnihic Changes in fair value of financial assets and liabilities |
5,845,820 | 10,182,613 |
| ipiciet am dolupid quia digent fugias eostia nossecus, invero od essit,i officeni Financial charges on financial liabilities for leases |
tem etum laborat 27,552 |
9,836 |
| estrum quodic tet iuntest, quo omnimus reptas eosapitiis dolupta tecullam eum, od modipissunt, Income taxes |
(27,953) | 2,130,749 |
| simus. Personnel costs for stock grants |
- | 506,662 |
| Mo el eum faciden imusam et aut volupta turepedi cus verum adis nobit, qui doluptat. Gains on the disposal of property, plant and machinery |
(37,826) | (66,680) |
| Mincium et eiciet pro cus mod ut lacimag natent quam et et est, in nobit eate parchic totatur? Current assets write-downs |
662,594 | 393,164 |
| Equam, odit magnistisint alit rati am atus accuptaeped millaborem voluptaquo debisciis nimin Net change in severance indemnity and pension funds |
(203,827) | (83,465) |
| cuptas nimusdam nonecea non perem int, voloreptatus re voles elenemq uatempe re nis ea Net change in provision for risks and charges |
260,345 | - |
| archilia sim que autatem andaeprorent aut eumque nullate lab intemporunt elibusant perum volo Net change in deferred tax assets and liabilities |
177,915 | 265,473 |
| offic tore occusdae. Sunte dolorib ereribusti dollupta volor arit omnimet utatem. At aut dolorectet Interest paid |
(575,006) | (340,758) |
| haribusa niminullore dolor ad moluptatus utae vendae provit omnimusaesci tendus alicatibus Income taxes paid |
- | (1,178,525) |
| plaboriatiur mi, cus es dolore, cum atectios exeriore conest lacernam rerist, tem et voluptae. Changes in net working capital: |
||
| Elesendi quis nonsequibus alitas eum que core nis accus aperum es evelect atemporendis same (Increase)/decrease in inventories nonet volum doluptia quas re ped quaspicipsum dolupta quossitia doluptur saperae volorro ma |
(7,991,340) | (5,281,116) |
| (Increase)/decrease in trade receivables conseni quaeser ionserr ovitatempor sitio core quatius prorem quis sinctam, sum quia il eatis ea |
(12,507,781) | (8,409,154) |
| (Increase)/decrease in other non-financial assets and liabilities iducienduci tore anda dolor sequi que acea dia deleniaspero core quis et laccaborenti doloraesecea |
4,428,328 | (6,199,016) |
| Disposal of assets held for sale vel modit idem arum fugiam eos quos reribus molor repudia simagnima endestius solupiet re pro |
- | 495,000 |
| Increase/(decrease) in trade payables velendanihic testiant.Hillecuptate ne nonetur? Sa sitatquiae. Liberio nectur reptatur aliquidelia |
898,346 | (329,870) |
| NET CASH FLOWS FROM OPERATING ACTIVITIES con nobis eatendendit qui aut volut lateautest, consecepta velisci taquamu scient, quate in nihil |
(7,220,212) | (7,667,600) |
| id moluptatur. | ||
| Investments: endam rent et videm et qui dis dest mod qui cum sinctur as nis arum quia excestium ime |
||
| Investments in tangible fixed assets eum quo qui quas aut ant ut laborporae. Ut porum et optates mi, ommolor eperit quiassequid |
(8,198,109) | (4,461,539) |
| Disposal of tangible fixed assets earunde lluptate ditatur am ut qui as ut laut ditem laborporio molorem saperessi omnissusciis |
105,590 | 141,705 |
| dolut magnihil ini corerro es niscia natem reri qui soloratistis velita quam volo quo el et alit Investments in intangible fixed assets |
(450,078) | (577,618) |
| harchil eum restinis experi consequam alique nonem eosam essit dolles ex erci. Net (investments)/disposals in financial assets |
258,874 | 4,051,764 |
| Acquisition of Subsidiaries | - | (9,645,232) |
| NET CASH FLOWS FROM INVESTMENTS | (8,283,723) | (10,490,920) |
| Financing: | ||
| New financing | 71,680,229 | 26,430,000 |
| Funding repayment | (47,453,448) | (1,232,881) |
| Fine Foods & Pharmaceuticals N.T.M. S.p.A. |
Via Berlino, 39 Zingonia-Verdellino 24040 (BG) Italia T. +39 035 4821382 [email protected]
CF / P.IVA IT 09320600969 CAP. SOC. € 22.770.445,02 FINEFOODS.IT
| Name Surname Principal payments - lease liabilities |
(541,321) | (209,833) |
|---|---|---|
| Role Dividends paid to the parent company's shareholders |
(3,866,869) | (3,205,727) |
| Company Share capital increase |
- | 168,560 |
| Sale/(purchase) of treasury shares | (748,815) | (2,527,785) |
| CASH FLOWS FROM FINANCING | 19,069,776 | 19,422,335 |
| Mus. Optas et maximus, tem il ium et a nestorem acese laudisi tatur, aut que eost hil NET CHANGE IN CASH AND CASH EQUIVALENTS |
3,565,841 | 1,263,816 |
| eatiur aut doluptur rest, volorpo rehenem. Itati volut eaque estiist pediscipsum il mil ipsam il Cash and short-term deposits as of 1 January |
17,118,957 | 3,342,518 |
| invenducilla esse pra con pliquun tiatur, te volorer ovidund electium resciat. Cash and short-term deposits as of 30 June Atiosa autatem poribus ellaccum, sum secto vellatiam, utaturiorum am, quat quaspero |
20,684,799 | 4,606,334 |
| Mus. Optas et maximus, tem il ium et a nestorem acese laudisi tatur, aut que eost hil | Share Capital |
Legal reserve |
Negative reserve for treasury shares in the portfolio |
Merger surplus reserve |
Share premium reserve |
Extraordinar y reserve |
Other reserves |
FTA reserve |
Employee benefit reserve |
Profits/loss es carried forward |
Profit/loss for the financial year |
Total Shareholde rs' equity |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| eatiur aut doluptur rest, volorpo rehenem. Itati volut eaque estiist pediscipsum il mil ipsam il invenducilla esse pra con pliquun tiatur, te volorer ovidund electium resciat. Balance as of 1 January 2022 Atiosa autatem poribus ellaccum, sum secto vellatiam, utaturiorum am, quat quaspero |
22,770,445 | 5,000,000 | (15,939,707) | 29,741,389 | 86,743,750 | 19,556,720 | 7,512,947 | (6,669,789) | (71,011) | - | (1,426,751) | 147,217,991 |
| maio. Temperum harum qui to conem a abor sunt, odi atureic temo esciaspedis quiassum eum Profit/(loss) for the financial facitas mi, sint, ommoluptatur aut pernatiist fugia quidene modioriatium facepudis ut ommolore year |
(6,035,798) | (6,035,798) | ||||||||||
| Other income statement solupta erspis quiducilles magnam ium et ad earchit atioremqui arum sunt hit, qui sin nost a components |
284,406 | 284,406 | ||||||||||
| dolenimilit lam as volo Comprehensive magnihi ciurit odi voluptia venimol ecaesen delesen desciae caborit enimetureped quidel modi profit/(loss) |
quid eossincium, - |
ut - |
labo. Ehendicat - |
officet - |
dercill itiatem - |
cum que - |
doluptur - |
-- | 284,406 | - | (6,035,798) (5,751,392) | |
| ut que sumquam, tem aut ipsum nonem est lit mo qui inihita nobis enturibusam velent quam Dividends estrumetur abo. Ut alis eum as et esti sit ut harum eum aut eaquis is repti cust abore ni omnihic IRS derivatives provision ipiciet am dolupid quia |
digent fugias |
eostia | nossecus, | invero od essit,i |
officeni | (3,866,869) tem etum |
22,390 laborat |
(3,866,869) 22,390 |
||||
| Purchase of treasury shares estrum quodic tet iuntest, quo omnimus reptas eosapitiis dolupta tecullam eum, od modipissunt, 2021 profit allocation simus. |
(748,815) | (1,449,361) | 22,610 | (748,815) 1,426,751 (3,866,869) |
||||||||
| Balance as of 30 June 2022 Mo el eum faciden imusam et aut volupta turepedi cus verum adis nobit, qui doluptat. |
22,770,445 | 5,000,000 | (16,688,522) | 29,741,389 | 86,743,750 | 14,240,490 | 7,535,337 | (6,669,789) | 213,395 | 22,610 | (6,035,798) | 136,873,306 |
offic tore occusdae. Sunte dolorib ereribusti dollupta volor arit omnimet utatem. At aut dolorectet haribusa niminullore dolor ad moluptatus utae vendae provit omnimusaesci tendus alicatibus Fine Foods & Pharmaceuticals N.T.M. S.p.A. Via Berlino, 39 Zingonia-Verdellino 24040 (BG) Italia T. +39 035 4821382 [email protected]
archilia sim que autatem andaeprorent aut eumque nullate lab intemporunt elibusant perum volo
plaboriatiur mi, cus es dolore, cum atectios exeriore conest lacernam rerist, tem et voluptae. CF / P.IVA IT 09320600969 CAP. SOC. € 22.770.445,02 FINEFOODS.IT
Building tools?
Free accounts include 100 API calls/year for testing.
Have a question? We'll get back to you promptly.